Zhao Wei, Zhang Xiuying, Rong Jianhui
Li Ka Shing Faculty of Medicine, School of Chinese Medicine, University of Hong Kong, Hong Kong, China.
Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Front Cardiovasc Med. 2021 Jul 28;8:701583. doi: 10.3389/fcvm.2021.701583. eCollection 2021.
Myocardial infarction is a prevalent and life-threatening cardiovascular disease. The main goal of existing interventional therapies is to restore coronary reperfusion while few are designed to ameliorate the pathology of heart diseases via targeting the post-translational modifications of those critical proteins. Small ubiquitin-like modifier (SUMO) proteins are recently discovered to form a new type of protein post-translational modifications (PTM), known as SUMOylation. SUMOylation and deSUMOylation are dynamically balanced in the maintenance of various biological processes including cell division, DNA repair, epigenetic transcriptional regulation, and cellular metabolism. Importantly, SUMOylation plays a critical role in the regulation of cardiac functions and the pathology of cardiovascular diseases, especially in heart failure and myocardial infarction. This review summarizes the current understanding on the effects of SUMOylation and SUMOylated proteins in the pathophysiology of myocardial infarction and identifies the potential treatments against myocardial injury via targeting SUMO. Ultimately, this review recommends SUMOylation as a key therapeutic target for treating cardiovascular diseases.
心肌梗死是一种常见且危及生命的心血管疾病。现有介入治疗的主要目标是恢复冠状动脉再灌注，而很少有治疗旨在通过靶向关键蛋白质的翻译后修饰来改善心脏病的病理状况。小泛素样修饰物（SUMO）蛋白最近被发现可形成一种新型的蛋白质翻译后修饰（PTM），即SUMO化。SUMO化和去SUMO化在维持包括细胞分裂、DNA修复、表观遗传转录调控和细胞代谢在内的各种生物学过程中动态平衡。重要的是，SUMO化在心脏功能调节和心血管疾病病理过程中起关键作用，尤其是在心力衰竭和心肌梗死中。本综述总结了目前对SUMO化和SUMO化蛋白在心肌梗死病理生理学中作用的认识，并确定了通过靶向SUMO来对抗心肌损伤的潜在治疗方法。最终，本综述推荐SUMO化作为治疗心血管疾病的关键治疗靶点。
